Reviva to Participate in the 4th Annual Roth Healthcare Opportunities Conference

Core Insights - Reviva Pharmaceuticals Holdings, Inc. is a late-stage pharmaceutical company focused on developing therapies for unmet medical needs in CNS, inflammatory, and cardiometabolic diseases [1][3] - The company will participate in the 4th Annual Roth Healthcare Opportunities Conference on October 9, 2025, where its CEO will engage in a panel discussion and host one-on-one investor meetings [1][2] Company Overview - Reviva's current pipeline includes two drug candidates: brilaroxazine (RP5063) and RP1208, both of which are new chemical entities discovered in-house [3] - The company has secured composition of matter patents for both drug candidates in the United States, Europe, and several other countries [3]